Voyager Therapeutics (NASDAQ:VYGR) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, BidAskClub reports.

Several other equities research analysts also recently issued reports on the stock. Benchmark assumed coverage on shares of Voyager Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $18.00 price objective on the stock. Morgan Stanley decreased their price target on shares of Voyager Therapeutics from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 4th. Oppenheimer assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, February 5th. They set an “outperform” rating and a $26.00 price target on the stock. Chardan Capital reiterated a “hold” rating and set a $20.00 price target on shares of Voyager Therapeutics in a research note on Friday, March 6th. Finally, ValuEngine raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, March 17th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Voyager Therapeutics currently has a consensus rating of “Buy” and an average target price of $20.61.

VYGR stock traded down $0.38 during midday trading on Thursday, hitting $8.84. 12,247 shares of the company traded hands, compared to its average volume of 506,668. Voyager Therapeutics has a twelve month low of $6.26 and a twelve month high of $28.79. The business has a 50 day simple moving average of $10.81 and a 200-day simple moving average of $13.67. The stock has a market capitalization of $316.92 million, a price-to-earnings ratio of -6.84 and a beta of 2.20.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.47. The business had revenue of $32.67 million for the quarter, compared to the consensus estimate of $9.25 million. Voyager Therapeutics had a negative net margin of 41.76% and a negative return on equity of 40.86%. Research analysts anticipate that Voyager Therapeutics will post -2.85 earnings per share for the current fiscal year.

In other news, CFO Allison Dorval sold 3,128 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.36, for a total transaction of $41,790.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andre Turenne sold 10,705 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.36, for a total value of $143,018.80. Following the transaction, the chief executive officer now owns 85,545 shares of the company’s stock, valued at $1,142,881.20. The disclosure for this sale can be found here. Insiders have sold a total of 17,557 shares of company stock valued at $234,562 over the last three months. Company insiders own 33.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC grew its position in shares of Voyager Therapeutics by 335.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,350 shares of the company’s stock valued at $60,000 after purchasing an additional 3,350 shares during the period. Victory Capital Management Inc. lifted its stake in Voyager Therapeutics by 46.0% in the 4th quarter. Victory Capital Management Inc. now owns 6,199 shares of the company’s stock valued at $86,000 after acquiring an additional 1,954 shares in the last quarter. AJO LP bought a new stake in Voyager Therapeutics in the 4th quarter valued at approximately $118,000. Jackson Wealth Management LLC bought a new stake in Voyager Therapeutics in the 4th quarter valued at approximately $120,000. Finally, Russell Investments Group Ltd. bought a new stake in Voyager Therapeutics in the 3rd quarter valued at approximately $139,000. Institutional investors own 82.19% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

See Also: Why are percentage gainers important?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.